These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23433847)

  • 1. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
    Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M
    Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.
    Frigerio B; Benigni F; Luison E; Seregni E; Pascali C; Fracasso G; Morlino S; Valdagni R; Mezzanzanica D; Canevari S; Figini M
    Immunol Lett; 2015 Nov; 168(1):105-10. PubMed ID: 26404855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PSMA
    Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
    J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.
    Mazzocco C; Fracasso G; Germain-Genevois C; Dugot-Senant N; Figini M; Colombatti M; Grenier N; Couillaud F
    Sci Rep; 2016 Mar; 6():23314. PubMed ID: 26996325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
    Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
    Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of
    Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
    Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
    Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.
    Nawaz S; Mullen GED; Blower PJ; Ballinger JR
    Nucl Med Commun; 2017 Aug; 38(8):666-671. PubMed ID: 28598898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camel heavy chain antibodies against prostate-specific membrane antigen.
    Evazalipour M; Tehrani BS; Abolhassani M; Morovvati H; Omidfar K
    Hybridoma (Larchmt); 2012 Dec; 31(6):424-9. PubMed ID: 23244321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
    Parker SA; Diaz IL; Anderson KA; Batt CA
    Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
    Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
    Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.